cagrilintide with semaglutide New in the August 14, 2025, issue of NEJM: Cagrilintide–Semaglutide for Overweight or Obesity (REDEFINE 1 phase 3a trial) Cagrilintide– for Overweight and Diabetes (REDEFINE 2 phase 3a trial) Cagrilintide vs semaglutide vs tirzepatide
Description
Research has identified effects on blood vessel formation, growth factor expression, nitric oxide production, and cellular signaling cascades
As a physician, youre aware that compounds like BPC-157 currently lack robust human clinical trials, and long-term safety, dosing standards, and management of potential adverse effects are still unclear
This is the run-in period where NNMT inhibition is being established
Injections may be given daily, weekly, or monthly and administered by a healthcare provider or self-administered at home under their guidance
5:e01185-85
Phase 3 trial of semaglutide in metabolic dysfunction-associated steatohepatitis
